Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY)

99 filings reported holding ADAPY - Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share as of Q2 2021.
Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) has 80 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 111,675,475 shares of 1,571,428,571 outstanding shares and own 7.11% of the company stock.
Largest 10 shareholders include Matrix Capital Management Company, LP (38,974,185 shares), NEA Management Company, LLC (17,082,611 shares), BAILLIE GIFFORD & CO (11,696,919 shares), BAKER BROS. ADVISORS LP (9,830,877 shares), Capital World Investors (8,002,700 shares), PFM Health Sciences, LP (3,627,900 shares), MORGAN STANLEY (2,288,479 shares), Point72 Asset Management, L.P. (2,059,092 shares), Avoro Capital Advisors LLC (2,024,400 shares), and JPMORGAN CHASE & CO (1,856,323 shares).
This table shows the top 80 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.